Open-Label, Exploratory Study to Evaluate the Effects of QR-010 on Nasal Potential Difference in Subjects With CF With the ΔF508 CFTR Mutation
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Eluforsen (Primary)
- Indications Cystic fibrosis
- Focus Proof of concept; Therapeutic Use
- Sponsors ProQR Therapeutics
- 16 Aug 2017 Final results of this study were orally presented at the European Cystic Fibrosis Conference, According to a ProQR Therapeutics media release.
- 15 Jun 2017 According to a ProQR Therapeutics media release, full data from this trial will be highlighted on R&D day 2017.
- 10 Jun 2017 Biomarkers information updated